Details of the Drug-Related molecule(s) Interaction Atlas

Amylin Drug Info

Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968

Cross-matching ID

PubChem CID

16132430

CAS Number

CAS 106602-62-4

TTD Drug ID

DMWDEN0

INTEDE Drug ID

DR1920

General Information of Drug (ID: DMWDEN0)

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanocortin receptor 4 (MC4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[3]
Bremelanotide	DM20LIM	Hypoactive sexual desire dysfunction	HA00	Approved	[4]
Setmelanotide	DMPVRN9	Obesity	5B81	Approved	[5]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[3]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[6]
PF-446687	DML38VU	Female sexual arousal dysfunction	HA01.1	Phase 2	[7]
AP-1030	DMBGA35	Metabolic disorder	5C50-5D2Z	Phase 1/2	[8]
PF-07258669	DM3CJ5N	Malnutrition	5B50-5B71	Phase 1	[9]
PT-14	DMYM9JL	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[10]
Melanotetan II	DMYK8MV	Obesity	5B81	Preclinical	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Matrix metalloproteinase-2 (MMP-2)	DE0LW4X	MMP2_HUMAN	Substrate	[2]
Matrix metalloproteinase-9 (MMP-9)	DEA0BDX	MMP9_HUMAN	Substrate	[2]

------------------------------------------------------------------------------------

References

1	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
2	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
3	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
7	Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
8	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9	Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
10	The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.